FDA Approvals and Pipeline Expansion Drive Bladder Cancer Therapeutics Market Growth
The bladder cancer therapeutics market is expanding with recent FDA approvals including INLEXZO for NMIBC and a KEYTRUDA-Padvev combination for MIBC, while the NMIBC market reached approximately USD 3 billion in 2025 across seven major markets. Ferring reported record revenues exceeding €2.5 billion in 2025, driven by Adstiladrin as its second major growth driver. A robust pipeline of emerging therapies is expected to further transform the market through 2036.
The bladder cancer therapeutics market is experiencing significant expansion driven by a series of recent FDA approvals, a robust pipeline of emerging therapies, and rising disease prevalence worldwide. Regulatory milestones in 2025 have broadened treatment options for both non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), while market analysts project continued growth through the next decade.
In September 2025, the FDA approved INLEXZO™ (gemcitabine intravesical system) from Johnson & Johnson for BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ (CIS), offering a new option for patients after failed BCG therapy or those ineligible for bladder removal surgery. In November 2025, the FDA granted approval for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) used in combination with Padcev® (enfortumab vedotin-ejfv) as neoadjuvant therapy followed by continued use as adjuvant therapy after cystectomy for adult patients with muscle-invasive bladder cancer who cannot receive cisplatin-based chemotherapy. This marks the first approved PD-1 inhibitor plus antibody-drug conjugate combination for this patient segment.
Prior approvals for NMIBC in the United States include KEYTRUDA in 2020, ADSTILADRIN in 2022, ANKTIVA in 2024, and ZUSDURI in 2025. In May 2025, however, the FDA's Oncologic Drugs Advisory Committee (ODAC) narrowly voted 5-4 against recommending approval of UGN-102 (mitomycin intravesical solution) from UroGen Pharma for treating recurrent, low-grade, intermediate-risk NMIBC.
The NMIBC pipeline remains active with numerous therapies in various stages of development. Promising candidates include CG0070 (cretostimogene grenadenorepvec) from CG Oncology, EG-70 (detalimogene voraplasmid) from enGene, TAR-210 from Janssen, Dabogratinib from Tyra Biosciences, UGN-103 from UroGen Pharma, TARA-002 from Protara Therapeutics, TLD-1433 from Theralase Technologies, LSAM-DTX (docetaxel) from NanOlogy, VAX014 from Vaxiion Therapeutics, Belzupacap sarotalocan from Aura Biosciences, and others. Analysts project that among all therapies, the highest revenue by 2036 is expected from cretostimogene grenadenorepvec ± KEYTRUDA.
In terms of market size, the total NMIBC therapeutics market across the seven major markets (the United States, the EU4 countries, the United Kingdom, and Japan) was approximately USD 2.35 billion in 2023 and grew to approximately USD 3 billion in 2025. The United States accounted for the largest market share in 2025. The total prevalent cases of NMIBC in the seven major markets were nearly 1.56 million, with the United States recording approximately 616,000 cases in 2023. These numbers are projected to increase over the forecast period through 2036.
The current standard of care for NMIBC primarily involves surgical intervention, intravesical Bacillus Calmette–Guérin (BCG) immunotherapy, and intravesical chemotherapy. Key growth drivers for the market include the rising global incidence of bladder cancer, particularly among aging populations, growing adoption of immunotherapy, and advancements in targeted intravesical drug delivery systems.
Ferring Pharmaceuticals reported that its total revenues for 2025 exceeded €2.5 billion, an increase of 10% from 2024, driven primarily by its flagship product Menopur®. The company noted a continued ramp-up in the United States for Adstiladrin® (nadofaragene firadenovec-vncg), a novel gene-based therapy for bladder cancer, confirming its position as Ferring's second major growth driver. Operating profit for the year reached €167 million, a decrease of €24 million versus the prior year at actual exchange rates, while remaining flat at constant exchange rates. Free cash flow generation approached neutral, representing a substantial improvement compared to the previous year.
Ferring also reported progress on sustainability goals, with its greenhouse gas emission reduction targets approved by the Science Based Targets initiative (SBTi). The company reduced Scope 1 and 2 emissions by 4.3% and Scope 3 emissions by 19% during 2025. Through its Project Family™: Safe Birth initiative, Ferring supplied approximately 1.7 million doses of Carbetocin at an affordable access price to low- and lower middle-income countries.
Among key pharmaceutical companies developing bladder cancer therapies are CG Oncology, Pfizer, UroGen Pharma, Janssen, Protara Therapeutics, AstraZeneca, BristolMyers Squibb, Merck, ImmunityBio, and Incyte Corporation. The market is anticipated to expand further through the forecast period, driven by increasing disease prevalence, the introduction of premium-priced treatment options, and a growing number of pharmaceutical companies actively developing therapies in this area.